Nuvation Bio Inc. (NUVB)
A
Pipeline Grade
Financial Position (from SEC Filings)
$125.4M
Cash & Equivalents
$5.1M
Quarterly Burn Rate
$1,655M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (1 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
TALETRECTINIB ADIPATE
IBTROZI |
APPROVED | Advanced Breast Cancer, Advanced Breast Carcinoma, Advanced Solid Tumor, Astrocytoma, Grade IV, Astrocytoma, IDH-Mutant, Grade 2, Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4, Breast Cancer, Breast Carcinoma, Breast Tumor, Bronchogenic Carcinoma, Cancer, Cancer of Breast, Cancer of Ovary, Cancer of Pancreas, Cancer of Prostate, Cancer of the Breast, Cancer of the Ovary, Cancer of the Pancreas, Cancer of the Prostate, Cancer, Therapy-Related, Carcinoma, Castrate Resistant Prostate Cancer, Castration Resistant Prostatic Neoplasms, Castration-resistant Prostate Cancer, Castration-Resistant Prostatic Cancer, Gene Fusion, Genetic Alteration, Glial Cell Tumors, Glioblastoma, Glioma, Glioma, Malignant, Glioma, Mixed, HER2-negative Breast Cancer, IDH1-mutant Glioma, Lung Diseases, Lung Neoplasms, Malignancies Multiple, Malignant Solid Tumor, Malignant Tumor of Breast, Metastatic Breast Cancer, Metastatic Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer (mCRPC), Molecular Sequenc |
Upcoming Catalysts
No upcoming catalysts detected for this company.